The Role of Targeted Therapy in Health-related Quality of Life in Generalized Myasthenia Gravis

Statement of Need

Generalized Myasthenia Gravis (gMG) is a chronic neuromuscular disorder that significantly impacts patients’ health-related quality of life (HRQoL). Despite advancements in disease management, many individuals with gMG continue to experience debilitating symptoms, persistent physical and mental fatigue, and challenges in daily activities. Current treatment options, including corticosteroids, intravenous immunoglobulins, and plasma exchange, are often limited by toxicity profiles, delayed onset of action, and inconsistent efficacy. Novel therapies such as FcRn antagonists and C5 complement inhibitors offer promising alternatives with targeted mechanisms of action and improved safety profiles.

This educational initiative aims to enhance clinician competence in evaluating the efficacy and safety of FcRn and C5 complement inhibitors and integrating formal HRQoL assessments, such as the MG-QOL15r, into gMG management. By bridging these gaps, healthcare providers can optimize treatment strategies, improve patient outcomes, and address the unmet needs of those living with gMG.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Incorporate formal assessment of HRQoL such as the Myasthenia Gravis QoL 15-item revised (MG-QOL15r), into individualized management of patients with gMG
Evaluate efficacy and safety data of FcRn antagonists as part of treatment decision-making for improving HRQoL outcomes across the continuum of gMG care
Utilize efficacy and safety data of C5 complement inhibitors as part of treatment decision-making for improving HRQoL outcomes across the continuum of gMG care

Financial Support

This activity is supported by educational grants from argenx and UCB.

Target Audience

Neuromuscular specialists, ophthalmologists, neurologists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007185-0000-25-037-H01-P).

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Physician Assistants (AAPA): 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 03/12/2026. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:

Dr. Vu reports the following financial relationships:

Advisory Board: Alexion Pharmaceuticals, Inc.; Amgen Inc.; argenx; Dianthus Therapeutics; and Johnson & Johnson

Consultant: Alexion Pharmaceuticals, Inc.; Dianthus Therapeutics; and ImmunAbs Inc.

Research Support: Alexion Pharmaceuticals; Inc.; Amgen Inc.; argenx; Cartesian Therapeutics, Inc.; COUR Pharmaceuticals; Dianthus Therapeutics; Johnson & Johnson; NMD Pharma; Regeneron; and UCB, Inc.

Speakers Bureau: Alexion Pharmaceuticals, Inc.; argenx; and CSL Behring

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Thomas Mitchell, MSW (Planning Committee)
Chelsey Goins, PhD (Planning Committee)
Estelle Perera (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

IN-011-031225-90

The Role of Targeted Therapy in Health-related Quality of Life in Generalized Myasthenia Gravis

Faculty

Statement of Need

Learning Objectives

Financial Support

Target Audience